Will bedaquiline become resistant? How to effectively avoid the development of drug resistance?

Bedaquiline (Bedaquiline) is an anti-tuberculosis drug used to treat multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). It belongs to the benzimidazole class of drugs. It effectively inhibits the growth of bacteria by inhibiting the ATP synthase in the respiratory chain of Mycobacterium tuberculosis. However, like other antibiotics, bedaquiline may face the development of resistance, which complicates patient treatment.

Bedaquiline resistance often occurs during irregular or incomplete treatment. Mycobacterium tuberculosis may become resistant to bedaquiline when patients do not take the drug at the prescribed dose or duration of treatment. The emergence of drug-resistant bacteria is also associated with insufficient drug concentrations, treatment interruption, or wrong drug combinations. If bedaquiline is not used in combination with other effective drugs, bedaquiline alone can easily lead to drug resistance.

How to avoid the occurrence of drug resistance

1.Strictly follow the treatment plan: In order to prevent the development of drug resistance, patients must take bedaquiline strictly according to the doctor's prescription and complete the entire treatment according to the recommended treatment cycle. Do not stop the medication or reduce the dose at will during treatment.

2.Combination therapy: Bedaquiline should not be used alone, but is usually used in combination with other effective anti-tuberculosis drugs to increase the therapeutic effect and reduce the incidence of drug resistance. Reasonable drug combination can subject Mycobacterium tuberculosis to multiple attacks and reduce the occurrence of drug-resistant bacteria.

3.Regular monitoring: Patients should undergo regular bacterial culture and drug susceptibility testing during treatment with bedaquiline to detect the emergence of drug-resistant bacteria. If bedaquiline resistance is found, doctors can promptly adjust the treatment plan and choose other effective drugs to continue treatment.

4.Patient education: Improving patients’ awareness of the problem of drug resistance, especially education about drug persistence and treatment integrity, can help reduce patients’ voluntary discontinuation of medication or skipping medication, thereby reducing the risk of drug resistance.

As an important drug in anti-tuberculosis treatment, bedaquiline resistance may occur due to irregular use and monotherapy. In order to effectively avoid the development of drug resistance, it is necessary to ensure that patients receive combined treatment in accordance with the standardized treatment plan, regularly monitor the treatment effect, and make timely adjustments. Through these measures, the risk of drug resistance can be significantly reduced and tuberculosis cure rates improved.

Reference materials:https://en.wikipedia.org/wiki/Bedaquiline